Disease · MONDO_0005723
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sertraline 400mg vs Placebo: Number of Participants Experiencing IRIS OR Relapse | 5 of 229 | 9 of 231 | 460 | NCT01802385 | Trial comparisons |
| Sertraline 400mg vs Placebo: Count of Participants With Cerebrospinal Fluid Sterility | 101 of 229 | 90 of 231 | 460 | NCT01802385 | Trial comparisons |
| Sertraline 400mg vs Placebo: Event Free Survival | 103 of 229 | 116 of 231 | 460 | NCT01802385 | Trial comparisons |
| Sertraline 400mg vs Placebo: Survival | 109 of 229 | 125 of 231 | 460 | NCT01802385 | Trial comparisons |
| Sertraline 400mg vs Placebo: deaths from any cause | 120 of 229 | 106 of 231 | 460 | NCT01802385 | Trial comparisons |
| Sertraline 400mg vs Placebo: serious adverse events | 141 of 229 | 121 of 231 | 460 | NCT01802385 | Trial comparisons |
| Low Dose Flucytosine vs Control: Mortality | 11 of 48 | 50 of 171 | 219 | NCT06414512 | Trial comparisons |
| Low Dose Flucytosine vs Control: deaths from any cause | 11 of 48 | 50 of 171 | 219 | NCT06414512 | Trial comparisons |
| Low Dose Flucytosine vs Control: serious adverse events | 31 of 48 | 132 of 171 | 219 | NCT06414512 | Trial comparisons |
| Low Dose Flucytosine vs Control: CSF Culture Sterility | 25 of 44 | 60 of 97 | 141 | NCT06414512 | Trial comparisons |
| 5FC Plus Fluconazole vs Fluconazole Alone: Number of Participants Alive at 12 Weeks | 2 of 3 | 2 of 3 | 6 | NCT01562132 | Trial comparisons |
| 5FC Plus Fluconazole vs Fluconazole Alone: serious adverse events | 0 of 3 | 0 of 3 | 6 | NCT01562132 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005723/comparisons